Docetaxel with or without estramustine for estramustine refractory castration-resistant prostate cancer: a single institution experience

BACKGROUND: The significance of combination of docetaxel (DTX) with estramustine phosphate (EMP) in castration-resistant prostate cancer (CRPC) patients remains unclear. In this study, we aimed to retrospectively evaluate the efficacy and toxicity of DTX with or without EMP and to elucidate the sign...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Nakano, Kazuhiko, Ohta, Shigeyuki, Komatsu, Kenji, Kubo, Taro, Nukui, Akinori, Suzuki, Kazumi, Kurokawa, Shinsuke, Kobayashi, Minoru, Morita, Tatsuo
Формат: Artigo
Язык:Inglês
Опубликовано: BioMed Central 2012
Предметы:
Research Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3305626/
https://ncbi.nlm.nih.gov/pubmed/22353627
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2490-12-3
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы